Intellectual Property

4-Antibody’s intellectual property portfolio comprises a growing number of patent families relating to antibody discovery and engineering technologies, and individual antibody drug candidates. For each case patent protection is pursued in all major pharmaceutical markets including the U.S. and Europe.

4-Antibody’s Retrocyte Display^® technology is described in WO 09/109368 and ongoing patent applications in other territories.

4-Antibody’s Hu-PAC^® technology is described in the granted US patent US7,741,077 and related granted patents in Europe, Australia, China, India and Japan.

4Ab-028, 4-Antibody’s lead anti-CMV product together with a large family of additional antibody constructs are described in the Company’s recently filed PCT application.